Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 342980, 7 pages
http://dx.doi.org/10.4061/2011/342980
Review Article

Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?

Unit of Gerontology and Geriatric Medicine, Department of Critical Care Medcine and Surgery, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy

Received 15 October 2010; Accepted 15 November 2010

Academic Editor: Benedetta Nacmias

Copyright © 2011 Enrico Mossello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Price, D. W. McKeel, V. D. Buckles et al., “Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease,” Neurobiology of Aging, vol. 30, no. 7, pp. 1026–1036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Reitz, L. Honig, J. P. Vonsattel, M. X. Tang, and R. Mayeux, “Memory performance is related to amyloid and tau pathology in the hippocampus,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 7, pp. 715–721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. R. Jack, V. J. Lowe, S. D. Weigand et al., “Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease,” Brain, vol. 132, no. 5, pp. 1355–1365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. McKhann, D. Drachman, and M. Folstein, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Google Scholar
  5. B. Dubois, H. H. Feldman, C. Jacova et al., “Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria,” The Lancet Neurology, vol. 6, no. 8, pp. 734–746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Holmes, D. Boche, D. Wilkinson et al., “Long-term effects of Aβ immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial,” The Lancet, vol. 372, no. 9634, pp. 216–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Di Carlo, M. Lamassa, M. Baldereschi et al., “CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia,” Neurology, vol. 68, no. 22, pp. 1909–1916, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Scheltens, N. Fox, F. Barkhof, and C. De Carli, “Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion,” The Lancet Neurology, vol. 1, no. 1, pp. 13–21, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. C. R. Jack, D. W. Dickson, J. E. Parisi et al., “Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia,” Neurology, vol. 58, no. 5, pp. 750–757, 2002. View at Google Scholar · View at Scopus
  10. R. Duara, D. A. Loewenstein, E. Potter et al., “Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease,” Neurology, vol. 71, no. 24, pp. 1986–1992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. T. Du, N. Schuff, X. P. Zhu et al., “Atrophy rates of entorhinal cortex in AD and normal aging,” Neurology, vol. 60, no. 3, pp. 481–486, 2003. View at Google Scholar · View at Scopus
  12. C. A. Raji, O. L. Lopez, L. H. Kuller, O. T. Carmichael, and J. T. Becker, “Age, Alzheimer disease, and brain structure,” Neurology, vol. 73, no. 22, pp. 1899–1905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. J. Bonte, M. F. Weiner, E. H. Bigio, and C. L. White, “Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients,” Radiology, vol. 202, no. 3, pp. 793–797, 1997. View at Google Scholar · View at Scopus
  14. L. Mosconi, “Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 4, pp. 486–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. D. H. S. Silverman, “Brain F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging,” Journal of Nuclear Medicine, vol. 45, no. 4, pp. 594–607, 2004. View at Google Scholar · View at Scopus
  16. Y. Yuan, Z. X. Gu, and W. S. Wei, “Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to alzheimer disease in patients with mild cognitive impairment: a meta-analysis,” American Journal of Neuroradiology, vol. 30, no. 2, pp. 404–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. S. Karow, L. K. McEvoy, C. Fennema-Notestine et al., “Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early alzheimer disease,” Radiology, vol. 256, no. 3, pp. 932–942, 2010. View at Publisher · View at Google Scholar
  18. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B,” Annals of Neurology, vol. 55, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. G. W. Small, V. Kepe, L. M. Ercoli et al., “PET of brain amyloid and tau in mild cognitive impairment,” The New England Journal of Medicine, vol. 355, no. 25, pp. 2652–2663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. R. Jack, D. S. Knopman, W. J. Jagust et al., “Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade,” The Lancet Neurology, vol. 9, no. 1, pp. 119–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. K. E. Pike, G. Savage, V. L. Villemagne et al., “β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease,” Brain, vol. 130, no. 11, pp. 2837–2844, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. Jack, V. J. Lowe, S. D. Weigand et al., “Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease,” Brain, vol. 132, no. 5, pp. 1355–1365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Hatashita and H. Yamasaki, “Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging,” Journal of Alzheimer's Disease, vol. 21, no. 3, pp. 995–1003, 2010. View at Publisher · View at Google Scholar
  24. J. C. Morris, C. M. Roe, E. A. Grant et al., “Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease,” Archives of Neurology, vol. 66, no. 12, pp. 1469–1475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Tolboom, W. M. van der Flier, M. Yaqub et al., “Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment,” Neurology, vol. 73, no. 24, pp. 2079–2085, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” The Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Blennow, “Cerebrospinal fluid protein biomarkers for Alzheimer's disease,” NeuroRx, vol. 1, no. 2, pp. 213–225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” The Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Monge-Argilés, J. Sánchez-Payá, C. Muñoz-Ruiz, A. Pampliega-Pérez, J. Montoya-Gutiérrez, and C. Leiva-Santana, “Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease,” Revista de Neurologia, vol. 50, no. 4, pp. 193–200, 2010. View at Google Scholar · View at Scopus
  30. A. Forsberg, O. Almkvist, H. Engler, A. Wall, B. Långström, and A. Nordberg, “High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters,” Current Alzheimer Research, vol. 7, no. 1, pp. 56–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. J. Bateman, G. Wen, J. C. Morris, and D. M. Holtzman, “Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker,” Neurology, vol. 68, no. 9, pp. 666–669, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. R. C. Petersen and J. Q. Trojanowski, “Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice,” Journal of the American Medical Association, vol. 302, no. 4, pp. 436–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Yanagida, M. Okochi, S. Tagami et al., “The 28-amino acid form of an APLPl-derived Aβ-like peptide is a surrogate marker for Aβ42 production in the central nervous system,” EMBO Molecular Medicine, vol. 1, no. 4, pp. 223–235, 2009. View at Publisher · View at Google Scholar
  35. Q. L. Ma, D. R. Galasko, J. M. Ringman et al., “Reduction of SorLA/LR11, a sorting protein limiting β-amyloid production, in alzheimer disease cerebrospinal fluid,” Archives of Neurology, vol. 66, no. 4, pp. 448–457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. O. M. Andersen, J. Reiche, V. Schmidt et al., “Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13461–13466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. C. R. Scherzer, K. Offe, M. Gearing et al., “Loss of apolipoprotein E receptor LR11 in Alzheimer disease,” Archives of Neurology, vol. 61, no. 8, pp. 1200–1205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Zhao, J. G. Cui, and W. J. Lukiw, “Reduction of sortilin-1 in Alzheimer hippocampus and in cytokine-stressed human brain cells,” NeuroReport, vol. 18, no. 11, pp. 1187–1191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Praticò, C. M. Clark, V. M. Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. Fitzgerald, “Increased 8,12-iso-iPF(2α)-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity,” Annals of Neurology, vol. 48, no. 5, pp. 809–812, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Praticò, C. M. Clark, F. Liun, V. Y. M. Lee, and J. Q. Trojanowski, “Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease,” Archives of Neurology, vol. 59, no. 6, pp. 972–976, 2002. View at Google Scholar · View at Scopus
  41. M. C. Boll, M. Alcaraz-Zubeldia, S. Montes, and C. Rios, “Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO content in the CSF. A different marker profile in four neurodegenerative diseases,” Neurochemical Research, vol. 33, no. 9, pp. 1717–1723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Schupf, M. X. Tang, H. Fukuyama et al., “Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14052–14057, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Blasko, G. Kemmler, S. Jungwirth et al., “Plasma amyloid beta-42 independently predicts both late-onset depression and alzheimer disease,” American Journal of Geriatric Psychiatry, vol. 18, no. 11, pp. 973–982, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. N. R. Graff-Radford, J. E. Crook, J. Lucas et al., “Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 64, no. 3, pp. 354–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. J. Locascio, H. Fukumoto, L. Yap et al., “Plasma amyloid β-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease,” Archives of Neurology, vol. 65, no. 6, pp. 776–785, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Mocali, S. Cedrola, N. Della Malva et al., “Increased plasma levels of soluble CD40, together with the decrease of TGFβ1, as possible differential markers of Alzheimer disease,” Experimental Gerontology, vol. 39, no. 10, pp. 1555–1561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Buchhave, S. Janciauskiene, H. Zetterberg, K. Blennow, L. Minthon, and O. Hansson, “Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease,” Neuroscience Letters, vol. 450, no. 1, pp. 56–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Desideri, F. Cipollone, S. Necozione et al., “Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role,” Neurobiology of Aging, vol. 29, no. 3, pp. 348–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Y. Calingasan, H. A. Erdely, and C. A. Altar, “Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury,” Neurobiology of Aging, vol. 23, no. 1, pp. 31–39, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. S. E. O'Bryant, G. Xiao, R. Barber et al., “A serum protein-based algorithm for the detection of Alzheimer disease,” Archives of Neurology, vol. 67, no. 9, pp. 1077–1081, 2010. View at Publisher · View at Google Scholar
  51. S. Ray, M. Britschgi, C. Herbert et al., “Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins,” Nature Medicine, vol. 13, no. 11, pp. 1359–1362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Britschgi and T. Wyss-Coray, “Blood protein signature for the early diagnosis of alzheimer disease,” Archives of Neurology, vol. 66, no. 2, pp. 161–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Angelucci, G. Spalletta, F. di Iulio et al., “Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels,” Current Alzheimer Research, vol. 7, no. 1, pp. 15–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Laske, E. Stransky, T. Leyhe et al., “Stage-dependent BDNF serum concentrations in Alzheimer's disease,” Journal of Neural Transmission, vol. 113, no. 9, pp. 1217–1224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Yu, Z. Zhang, Y. Shi et al., “Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese han,” Journal of Clinical Psychiatry, vol. 69, no. 7, pp. 1104–1111, 2008. View at Google Scholar · View at Scopus
  56. L. Gasparini, M. Racchi, G. Binetti et al., “Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease,” FASEB Journal, vol. 12, no. 1, pp. 17–34, 1998. View at Google Scholar · View at Scopus
  57. Y. Nagasaka, K. Dillner, H. Ebise et al., “A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 41, pp. 14854–14859, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Y. Wang, M. R. Pisano, and E. Friedman, “Attenuated protein kinase C activity and translocation in Alzheimer's disease brain,” Neurobiology of Aging, vol. 15, no. 3, pp. 293–298, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Govoni, S. Bergamaschi, M. Racchi et al., “Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients,” Neurology, vol. 43, no. 12 I, pp. 2581–2586, 1993. View at Google Scholar · View at Scopus
  60. W. Q. Zhao, L. Ravindranath, A. S. Mohamed et al., “MAP kinase signaling cascade dysfunction specific to Alzheimer's disease in fibroblasts,” Neurobiology of Disease, vol. 11, no. 1, pp. 166–183, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. T. K. Khan and D. L. Alkon, “An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13203–13207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. T. K. Khan and D. L. Alkon, “Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker,” Neurobiology of Aging, vol. 31, no. 6, pp. 889–900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. H. W. Klafki, P. Lewczuk, H. Kamrowski-Kruck et al., “Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form,” Journal of Alzheimer's Disease, vol. 18, no. 3, pp. 613–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Uberti, C. Lanni, T. Carsana et al., “Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients,” Neurobiology of Aging, vol. 27, no. 9, pp. 1193–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Lanni, D. Uberti, M. Racchi, S. Govoni, and M. Memo, “Unfolded p53: a potential biomarker for Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 12, no. 1, pp. 93–99, 2007. View at Google Scholar · View at Scopus
  66. C. Lanni, M. Racchi, G. Mazzini et al., “Conformationally altered p53: a novel Alzheimer's disease marker?” Molecular Psychiatry, vol. 13, no. 6, pp. 641–647, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Lanni, M. Racchi, S. Stanga et al., “Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 20, no. 1, pp. 97–104, 2010. View at Publisher · View at Google Scholar
  68. D. Uberti, G. Cenini, S. A. Bonini et al., “Increased CD44 gene expression in lymphocytes derived from alzheimer disease patients,” Neurodegenerative Diseases, vol. 7, no. 1–3, pp. 143–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Padovani, L. Pastorino, B. Borroni et al., “Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD,” Neurology, vol. 57, no. 12, pp. 2243–2248, 2001. View at Google Scholar · View at Scopus
  70. B. Borroni, F. Colciaghi, C. Caltagirone et al., “Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type a 2-year follow-up study,” Archives of Neurology, vol. 60, no. 12, pp. 1740–1744, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. B. Borroni, C. Agosti, E. Marcello, M. Di Luca, and A. Padovani, “Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets,” Experimental Gerontology, vol. 45, no. 1, pp. 53–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. D. A. Butterfield, T. Reed, S. F. Newman, and R. Sultana, “Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment,” Free Radical Biology and Medicine, vol. 43, no. 5, pp. 658–677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. J. N. Keller, F. A. Schmitt, S. W. Scheff et al., “Evidence of increased oxidative damage in subjects with mild cognitive impairment,” Neurology, vol. 64, no. 7, pp. 1152–1156, 2005. View at Google Scholar · View at Scopus
  74. P. Rinaldi, M. C. Polidori, A. Metastasio et al., “Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease,” Neurobiology of Aging, vol. 24, no. 7, pp. 915–919, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. D. L. Marcus, C. Thomas, C. Rodriguez et al., “Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease,” Experimental Neurology, vol. 150, no. 1, pp. 40–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Padurariu, A. Ciobica, L. Hritcu, B. Stoica, W. Bild, and C. Stefanescu, “Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease,” Neuroscience Letters, vol. 469, no. 1, pp. 6–10, 2010. View at Publisher · View at Google Scholar · View at Scopus